| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Introduction
The organ transplant market, though growing only slowly in recent years,
offers substantial opportunities for drug developers. This market encompasses
therapies that must be taken lifelong, ensuring a steady stream of revenue
throughout a drug's life cycle. Another attractive feature of this market is
that it can serve as a gateway to other, potentially more lucrative markets.
Get the Answers You Need to Shape Your Strategy
- Although the organ transplant market has seen slow growth, certain
segments of the market offer greater opportunities. What factors are
constraining this market? Will growth accelerate in coming years? Which
markets offer the greatest potential rewards?
- Current anti-rejection therapies provide satisfactory effi cacy, but their
side-effect profi les are a safety concern. Which current therapies are
associated with the most serious effects? What are the greatest unmet needs in
this market? How can companies capitalize on these needs as they develop new
therapies?
- Two leading agents in this market, Astellas's Prograf and Roche/Chugai's
Cellcept, will soon go off-patent. What will the advent of increased
generic competition mean for the market? Which agents will become the new
market leaders?
Scope
- Biology of transplant rejection: immune response in tissue
rejection, natural killer cell response, types of rejection, post-transplant
survival rates.
- Prevalence of organ transplantation: number of transplants
performed per year (including projections through 2017), number of transplants
per organ, number of transplants by age-group.
- Current therapies: treatment after transplantation, commonly used
maintenance therapies.
- Market for anti-rejection therapies: emerging therapies,
long-acting tacrolimus, CP-690550, belatacept.
- Market outlook: drivers, constraints, development strategies.
TABLE OF CONTENTS
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Biology of Transplant Rejection
- Immune Response in Tissue Rejection
- T-Cell Activation
- B-Cell Activation
- Natural Killer Cell Response
- Types of Rejection
- Importance of HLA Matching in Preventing Organ Rejection
- Post-Transplant Survival Rates
- Prevalence of Organ Transplantation
- Current Therapies
- Treatment After Organ Transplantation
- Overview of Commonly Used Agents for Maintenance Therapy
- Azathioprine
- Corticosteroids
- Cyclosporine
- Mycophenolate
- Sirolimus
- Tacrolimus
- 2007 Market for Anti-Rejection Therapies
- Emerging Therapies and Their Commercial Potential
- Long-Acting Tacrolimus
- CP-690550
- Belatacept
- Outlook: Drivers, Constraints, and Development Strategies
Tables
- 1. Immune System Mediators and Their Functions
- 2. U.S. Sales of Leading Branded Agents (Organ Transplant Market Only) to
Prevent Organ Rejection, 2007
- 3. Agents in U.S. Development for the Prevention of Chronic Rejection, 2007
Figures
- 1. Number of U.S. Organ Transplantations, 1988-2017
- 2. Number of U.S. Organ Transplants, by Organ, 2007
- 3. Mechanism of Action of Current Anti-Rejection Agents
- 4. U.S. Market Growth of Anti-Rejection Agents, 2000-2007
- 5. U.S. Market Share of Leading Anti-Rejection Agents, 2007
- 6. U.S. Prescribing Share of Leading Anti-Rejection Agents, 2007
|
